Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study

Proton pump inhibitors (PPIs) increase mortality[1][5][6], gastric cancer[2], hip fractures[3], chronic kidney disease[6], major cardiovascular events[5].
PPIs clinical efficacy was proved minimal. [4]
References
[1] https://bmjopen.bmj.com/content/7/6/e015735
[2] https://gut.bmj.com/content/67/1/28
[3] https://link.springer.com/article/10.1007/s00198-018-4788-y
[4] https://www.nejm.org/doi/full/10.1056/NEJMoa1714919
[5] https://www.ncbi.nlm.nih.gov/pubmed/29233498
[6] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4973085/